CurrentCignaPolicy IP0542

Vabysmo (faricimab-svoa) intravitreal injection coverage

Cigna's coverage policy for Vabysmo (faricimab-svoa) intravitreal injection detailing prior authorization, approved indications, dosing limits, and specific employer/individual plan criteria. Applies to providers submitting claims for Vabysmo under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyVabysmo (faricimab-svoa) intravitreal injection coverage

Policy CodePolicy IP0542

Change TypeCriteria and coverage updates (dosing clarification, preferred product rules, expanded indications, new exclusion)

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization demonstrating the indication, that dosing is 6 mg per eye with interval not more frequent than every 4 weeks, and preferred product documentation when required.

SourceLink

POLICY UPDATE CHANGES

Dosing language clarified to state the requested dose must be 6 mg per eye and dosing interval not more frequent than once every 4 weeks for each eye being treated.

Preferred product criteria added requiring documentation of current Vabysmo therapy or failure/contraindication/intolerance to repackaged bevacizumab or prescriber concerns about safety/supplier.

Other neovascular diseases of the eye were added as an approvable condition with examples listed.

New exclusion: concomitant use with another intravitreal VEGF inhibitor is not medically necessary.

3FDA‑approved indications listed

6 mgrequired per‑eye dose for approvals

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Policy and Medical Necessity

Preferred Product / Step Therapy

Employer Plans and Individual and Family Plans — preferred product criteria (one of the following):

Preferred product criteria (Employer/Individual plans)

A: Patient is currently receiving therapy with Vabysmo.
B
- i.a: Previously tried repackaged bevacizumab AND demonstrated inadequate efficacy or intolerability.
- i.b: For diabetic macular edema (DME), baseline ETDRS best-corrected visual acuity (BCVA) of 20/50 or worse (<69 ETDRS letters).
- i.c: Prescriber documents that the safety of repackaged bevacizumab is of significant concern.
- i.d: Prescriber documents supplier concerns regarding repackaged bevacizumab (as applicable).

ref

Concomitant intravitreal administration of Vabysmo with another intravitreal vascular endothelial growth factor (VEGF) inhibitor is explicitly excluded. There is no evidence to support concurrent use of Vabysmo and any other intravitreal VEGF agent, and such combination therapy is considered not medically necessary for coverage purposes.

Use of Vabysmo for any indication or clinical scenario not described in this policy’s coverage criteria is considered not medically necessary. This expressly includes the concomitant intravitreal use of Vabysmo with another VEGF inhibitor and other off‑label or unproven combinations for which the policy provides no approval.

Billing and Code Information

Covered HCPCS CodesHCPCSCovered

J2777

Injection, faricimab-svoa, 0.1 mg

Dosing interval definition — every 4 weeks

DefinitionEvery 4 weeks = approximately every 28 ± 7 days.

Clinical contextUsed as the standard ‘every 4 weeks’ dosing interval for Vabysmo across DME, RVO, and neovascular AMD regimens.

Regimen noteFor DME and neovascular AMD, initial monthly dosing (every 4 weeks ≈ 28 ±7 days) is specified for the first doses before potential interval extension.

Dosing interval 'every 4 weeks' definition (alternate)

Alternate displayEvery 4 weeks (approximately every 28 ± 7 days).

Numeric equivalenceApproximately 28 days with an allowable ±7 day window for scheduling flexibility.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior authorization required — indication, dose, interval, and prescriber

Prior authorization is required for Vabysmo. Approval is recommended only when the patient meets the indication-specific criteria and dosing requirements: the dose must be 6 mg administered by intravitreal injection for each eye being treated and the dosing interval must not be more frequent than once every 4 weeks (approximately every 28 ± 7 days). Vabysmo must be prescribed by or in consultation with a physician who specializes in the condition (ophthalmologist).

Dose: 6 mg intravitreal injection per eye.
Interval: not more frequent than once every 4 weeks (≈28 ± 7 days).
Prescribed by or in consultation with an ophthalmologist.

Step Therapy

Step therapy / preferred product requirements for employer and individual plans

For Employer Plans and Individual and Family Plans, one of the preferred-product pathways must be met before approval: the patient is currently receiving Vabysmo OR the patient previously tried repackaged bevacizumab with documented inadequate efficacy or intolerability; alternatively, for DME the patient may have baseline ETDRS BCVA 20/50 or worse (<69 letters), or the prescriber may document safety concerns about repackaged bevacizumab or supplier concerns.

Definitions and Examples

Other Neovascular Diseases of the Eye — examples

Examples — angioid streaksAngioid streaks (may be secondary to systemic conditions such as pseudoxanthoma elasticum, Paget's disease of bone, and sickle cell disease).

Iris neovascularizationIris neovascularization.

Neovascular glaucomaNeovascular glaucoma.

Pachychoroid neovasculopathyPachychoroid neovasculopathy.

Polypoidal choroidal vasculopathyPolypoidal choroidal vasculopathy.

Presumed ocular histoplasmosis syndromePresumed ocular histoplasmosis syndrome.

Background and Drug Information

Vabysmo (faricimab‑svoa) is an intravitreal biologic that inhibits both vascular endothelial growth factor (VEGF) and angiopoietin‑2 (Ang‑2). Overexpression of VEGF contributes to pathologic retinal neovascularization and vascular leakage leading to macular edema and vision loss; inhibition of VEGF (and Ang‑2) reduces neovascularization and macular edema across several retinal disorders. Vabysmo is FDA‑approved for treatment of diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and neovascular (wet) age‑related macular degeneration (AMD).

Documentation Required

Required documentation to support prior authorization

Prior authorization requests must document that the medication is prescribed by or administered under the supervision of an ophthalmologist and include the indication plus dosing details showing 6 mg per eye and a dosing interval not more frequent than once every 4 weeks (≈28 ± 7 days). For employer/individual plans, include documentation of preferred-product status (currently receiving Vabysmo or evidence of trial/failure/contraindication/intolerance to repackaged bevacizumab or prescriber safety/supplier concerns).

Prescriber specialty: ophthalmologist (or documentation of consultation).
Indication for use (FDA‑approved or supported neovascular eye disease).
Dosing: 6 mg per eye and interval not more frequent than once every 4 weeks (≈28 ± 7 days).
Preferred-product documentation for employer/individual plans (current Vabysmo OR trial/failure/contraindication/intolerance to repackaged bevacizumab or prescriber safety/supplier concerns).